Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07853053) titled 'DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer' on Sept. 27.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Condition:
Bladder Cancer
Intervention:
Drug: Disitamab Vedotin
Drug: Toripalimab
Drug: Cetirizine
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: January 1, 2027
Target Sample Size: 20
Countries...